Pomona’s GRE1 Receives EMA Orphan Drug Designation for PML
Pomona is pleased to announce that GRE1, an investigational therapeutic candidate for Progressive Multifocal Leukoencephalopathy (PML), a rare and life-threatening neurological disease caused by the reactivation of the JC virus (JCV), has received Orphan Drug Designation (ODD) from the European Medicines Agency (EMA). This designation represents an important mi
Therapeutic antibodies: precision medicine for multiple diseases
The potentiality of Monoclonal Antibodies (mAbs) From its discovery, the humoral immune system has always been considered as a fundamental weapon for our health able to defend the body against antigens derived from microorganisms, viruses and everything which is considered alien to the body, as antigens expressed on cancer cells. Due to this, antibodies are [&h
